Stability of pro- and anti-inflammatory immune biomarkers for human cohort studies
- 1.3k Downloads
Although discovery research has identified the importance of dozens of pro- and anti-inflammatory immune mediators in the pathogenesis, maintenance, exacerbation and resolution of inflammatory diseases, most human cohort studies have incorporated few or no immunological intermediate phenotypes in their analyses. Significant hindrances have been (1) the limited panel of biomarkers known to be readily detected in healthy human populations and (2) the stability, hence utility, of such biomarkers to repeated analysis.
The frequency and stability of 14 plasma biomarkers linked to in vivo immune regulation of allergic and autoimmune inflammatory disorders was determined in 140 healthy pediatric and adult participants. The impact of initial and multiple subsequent freeze/thaw cycles on pro-inflammatory (CCL2, CXCL10, IL-18, TNFα, IL-6), anti-inflammatory (IL-10, sTNF-RII, IL-1Ra), acute phase proteins (CRP, PTX3) and other biomarkers (sST2, IL-1RAcP) was subsequently quantified.
Multiple biomarkers capable of providing an innate immune signature of inflammation were readily detected directly ex vivo in healthy individuals. These biomarker levels were unaffected when comparing paired data sets from freshly obtained, never frozen plasma or serum and matched aliquots despite extensive freeze/thaw cycles. Neither age nor sex affected stability. Similarly, no quantitative differences were found following repetitive analysis of inflammatory biomarkers in culture samples obtained following in vitro stimulation with TLR and RLR ligands.
A broad panel of in vivo and ex vivo cytokine, chemokine and acute phase protein biomarkers that have been linked to human chronic inflammatory disorders are readily detected in vivo and remain stable for analysis despite multiple freeze thaw cycles. These data provide the foundation and confidence for large scale analyses of panels of inflammatory biomarkers to provide better understanding of immunological mechanisms underlying health versus disease.
KeywordsCohort Inflammation Human immunology Immune regulation Innate Allergy Autoimmunity
peripheral blood mononuclear cells
pattern recognition receptor
toll like receptor
Cohorts that range from hundreds to tens of thousands of individuals offer a powerful tool to validate, integrate and extend multidisciplinary findings obtained in basic biomedical discovery research. Currently, many human cohorts focus on identifying correlates of environmental variables (i.e. endotoxin exposure, birth order) with clinical outcomes. With few exceptions [1, 2, 3], only a small proportion of such publications provide detailed examination of the intermediate phenotype of in vivo cytokine responses. For example, for allergic diseases, the most common chronic immune disorder in humans, PubMed identifies over 2000 publications for “birth cohort and allergy,” but <10% (155 citations) incorporate “cytokine or IL*,” and of these, only a subset examine inflammatory cytokines. Recent meta-analyses identify the knowledge gap resulting from this omission [4, 5, 6, 7, 8]. Given that most allergic and autoimmune disorders are driven by dysfunctional immune regulation, this identifies an important, but often missed, opportunity to enhance understanding of endotypes and mechanisms [9, 10, 11, 12] underlying inflammatory diseases. The importance of doing so is increasingly clear [13, 14, 15, 16, 17, 18, 19, 20, 21, 22].
A major logistical challenge that impedes more widespread adoption of such analyses is continuing uncertainty about the stability of immune biomarkers in plasma, serum or tissue culture samples to repeated analysis. Repetitive freezing and thawing (F/T) cycles can induce protein instability and aggregation [23, 24]. Among immune biomarkers in complex biological fluids (i.e. plasma, culture supernatants), some studies indicate extreme sensitivity, while others report that minimal variance results from the limited number of F/T cycles that are typically required. This controversy may arise from the limited number of cytokine biomarkers that have been examined to date, the small sample sizes often utilized (i.e. frequently < 10 individuals), the fact that several biomarkers examined are typically undetectable or at the limits of assay sensitivity in much of the healthy population examined (i.e. IL-6), hence substitution of spiked recombinant commercial proteins occurs as a surrogate for in vivo biomarkers. To an even greater extent than discovery based research projects which examine 20–40 individuals, cohorts face extensive logistical difficulties that prohibit analyses without repeated cycles of F/T [25, 26, 27].
Here we test the hypothesis that exposure of immune pro- and anti-inflammatory biomarkers to at least five repeated F/T cycles introduces acceptable (i.e. minimal and predictable) variation. Using a panel of 14 pro-inflammatory (CCL2, CXCL10, IL-18, TNFα, IL-6), anti-inflammatory (IL-10, sTNF-RII, IL-1Ra), acute phase proteins (CRP, PTX3) and other biomarkers (sST2, IL-1RAcP) of inflammatory disorders previously linked to asthma, other atopic disorders [28, 29, 30, 31] and a wide range of other chronic inflammatory conditions in humans, we quantify the sensitivity to initial freezing as well as to repeated F/T cycles that are inevitable if large studies incorporate analyses of immunological intermediate phenotypes. The findings demonstrate that a broad panel of pro-inflammatory, anti-inflammatory, acute phase proteins and other biomarkers of inflammatory diseases are readily amenable to analysis and should be more widely incorporated in large human cohort studies.
The Canadian Healthy Infant Longitudinal Development (CHILD) Study is a prospective longitudinal birth cohort of >3500 neonates . In this report, following approval by the University of Manitoba Health Research Ethics Board, and written informed consent from each participant or their parent/guardian, non-fasting venous blood was obtained at the Winnipeg site to yield plasma and serum samples from 140 randomly selected participants (children and their parents).
Peripheral blood was collected by venipuncture and used for plasma, serum and isolation of PBMC . Briefly, samples were kept at room temperature during transport and prior to processing. Plasma was collected from 10-mL heparin Vacutainer tubes (BD, Mississauga, Canada) by centrifugation (500g, 10 min). Serum was collected from 6-mL silica-coated Vacutainer tubes (BD) by centrifugation (1000g, 10 min). Replicate plasma and serum sample aliquots (300 μL each) were prepared from each individual and then used within 24 h without freezing and were frozen at −80 °C for one or five F/T cycles before analysis. All analyses were performed comparing paired samples from the same individuals. Because the goal was to determine the impact of repeated changes of state (i.e. freeze/thawing) on plasma and supernatant samples, rather than how many months or years a sample could be stored and retain its integrity, all samples that underwent freeze thaw cycles were carried out within 24 h when comparing never frozen plasma or culture supernatant with samples subjected to one or five F/T cycles. Paired analyses of one versus five F/T cycles were carried out with storage at −80 °C for a few days to a month in total. Samples were handled using standard laboratory conditions: thawed rapidly at 37 °C then kept on ice until analyzed.
PBMC isolation and cell culture
PBMC were prepared using Ficoll (GE Healthcare, Mississauga, Canada) and cultured (triplicates, 350,000 cells/round bottom well in 200 μL, 24 h) in medium alone or with stimuli. Medium consisted of RPMI-1640 (Thermo Fisher Scientific, Mississauga, Canada) supplemented with 10% fetal bovine serum (GE Healthcare, Mississauga, Canada), 1% l-glutamine (VWR International, Mississauga, Canada), 1% Antibiotic–Antimycotic (Thermo Fisher Scientific), and 0.1% 2-mercaptoethanol (Thermo Fisher Scientific). Innate stimuli used included TLR4 ligand LPS (0.4 ng/mL, InvivoGen, San Diego, CA) or RLR ligand Poly(I:C)/Lyovec (250 ng/mL, InvivoGen). All PBMC samples were cultured the day they were drawn. Supernatants were aliquoted and examined in parallel without ever freezing and after five F/T cycles at −80 and 37 °C.
All analyses were carried out in duplicate with paired samples after 0–5 F/T cycles. 5% of sample pairs or triplets were repeated on a separate day. Meso Scale Discovery (MSD, Rockville, Maryland) singleplex assays were used to analyze plasma, serum and culture supernatants for CCL2, CRP, CXCL8, IL-6, IL-10, IL-18, IL-1Ra, sTNF-RII and TNFα according to manufacturer`s instructions. MSD V-Plex assays were used to analyze plasma and supernatant levels of CXCL10. ELISA (alkaline phosphatase-biotin coupled developing reagent with PNPP for development) was used to analyze plasma and serum levels of IL-1RAcP, PTX3, and sST2 (R&D Systems, Minneapolis, Minnesota) using ultrasensitive protocols as previously described . ELISAs incorporated four serial dilutions of each sample (i.e. 1/2, 1/4, 1/8 and 1/16) that were assessed against eight serial dilutions of fresh aliquots of a constant recombinant lab standard stored at −80 °C in individual 400 μL aliquots (Cedarlane, Burlington, Canada; PeproTech, Quebec, Canada; R&D Systems). In most experiments, median coefficients of intra-assay variation between assays were below 5% for MSD assays and 10–15% for ELISA. Inter-assay variation was typically <10–20%.
Data were analyzed using GraphPad Prism (La Jolla, California). Each point represents a single sample from an individual aliquot that has undergone the indicated number of F/T cycles. Mann–Whitney or Wilcoxon Matched Pairs/Signed Rank tests were used for unpaired and paired data sets respectively. While the multiple comparisons used in this study would normally require use of Bonferroni corrections, to obtain maximum sensitivity for detection of possible differences, significance was assessed at the lower threshold of a 95% confidence level (two-tailed p < 0.05).
Detection and stability of pro- and anti-inflammatory plasma biomarkers
Freshly obtained plasma (or sera, see below) from a study population of 140 individuals of whom 30 were pediatric were examined. Adults were 20–44 years of age (median 32 year), while the pediatric population was aged 3 (median 3.2 year). Due to the number of biomarkers examined, and logistical constraints on how many independent assays could be performed simultaneously with never frozen samples, slightly different numbers of individuals were examined for each biomarker.
A single exception was found among the 14 biomarkers examined. sTNF-RII differed when comparing 1× versus 5× F/T cycles (medians 1516 vs. 1470 pg/mL, a 3% increase, p = 0.002). We note that comparison of never frozen plasma and 5× F/T was not significant (medians 1470 vs. 1516 pg/mL, p = 0.14). For context, the 3% difference seen comparing one and five F/T cycles contrasts with the 770% range (560–4365 pg/mL) in the population. Thus, while the 1× versus 5× F/T is statistically significant (if it had not been corrected for multiple comparisons, as would normally be performed), the biological relevance of a median 3% error in analysis elicited by freezing and thawing is minor in comparison to a 7.7 fold range in the population.
Stability of systemic inflammatory biomarkers: CRP, PTX3, IL-1RAcP and sST2
Serum versus plasma stability to repeated F/T handling
Impact of donor age or sex on F/T stability
Stability of PRR-stimulated responses generated in primary culture
Human inflammatory disease research is hampered by use of a relatively small number of biomarkers to translate findings from basic biomedical research into large scale cohorts. Here we demonstrate a panel of 14 in vivo biomarkers of pro- and anti-inflammatory status that are readily quantifiable in plasma of healthy adult and pediatric populations. The results also demonstrate that no differences are evident when comparing fresh/never frozen samples with those that had undergone up to five F/T cycles. Similarly, a panel of biomarkers of innate PRR-mediated activation remained stable in supernatants obtained after cell culture stimulation, directly ex vivo, despite repeated freeze thaw cycles. Thus, extending findings from individual murine and human analyses of inflammatory disorders to large human cohorts by obtaining more comprehensive innate immune signatures is readily feasible.
Prior literature on F/T stability has yielded contradictory conclusions. A representative early study (with four healthy and three HIV-infected volunteers) indicated F/T stability for the biomarkers examined  as did similar studies [36, 37]. Others disagreed, finding substantial sensitivity to F/T [38, 39, 40, 41]. Using four healthy individuals, De Jager et al.  concluded that samples for cytokine measurements could not be subjected to repeated F/T cycles because only two of the 15 cytokines they examined did not show alterations in mean levels.
Important caveats to be aware of in interpretation of the literature include: (1) due to limited assay sensitivity, many investigators utilized samples spiked with recombinant cytokines to achieve sufficient sensitivity for the assays employed, (2) the number of individuals studied in most studies was often less than ten, (3) intra- and inter-assay variation was often not provided, making it difficult to determine to what extent decreases or increases in reported cytokine levels were attributable to variability in assay or operator performance rather than F/T cycles. Moreover, in many studies, means and parametric statistical tests with significance set at 0.05 were utilized, without correction for non-parametric data distributions (log-transformation or use of non-parametric tests such as utilized above) common to small data sets or correcting for multiple comparisons (i.e. Bonferroni corrections).
When statistically significant differences are identified, it will be important to examine the scale of such differences in the context of the population being examined. For example, here, sTNF-RII levels were significantly different following one versus five F/T cycles (medians 1516 vs. 1470 pg/mL, a 3% increase, p = 0.002). While variance is inherent in repeated analyses of any quantitative measure, it needs to be compared in scale to the range exhibited within the study population as a whole. Thus, for sTNFRII, there is a 770% (560–4365 pg/mL) range in values within the population studied. Similarly, the ranges of CXCL10 (2500% or 25-fold range between weakest and strongest), IL-18 (>125 fold), TNFα (>1000 fold) and IL-10 (>3000 fold) seen in this relatively small human population (n = 140) are important to weigh in assessing biological as well as statistical significance even when a small, statistically significant difference is contributed by sample handling.
This study has important caveats. The focus here was on the capacity to reproducibly quantify pro-/anti-inflammatory biomarker concentrations ex vivo, despite virtually inevitable F/T cycles. We did not attempt to determine biological activity (i.e. therapeutic potential), nor did we assess the stability of recombinant proteins in these assays. Other (largely controllable) factors can introduce sample variability and, depending on the study design utilized, need to be considered individually. Similarly, immune biomarkers such as Type I or III Interferons (18) that were not examined in this study may exhibit sensitivity to F/T cycles. As additional biomarkers are added, it will be important to examine each explicitly prior to undertaking large-scale analyses. Other controllable variables, including operator error, assay variance and so forth may also introduce variance. This underlines the need for well-defined standard operating procedures (SOPs). Finally, proving that something does not occur is impossible. For that reason, this study utilized well over 100 different individuals. Variation might become detectable if 1000 or 100,000 individuals were examined, but if thousands or more samples are required to detect a difference, the size of that effect would by definition be minor.
One concern not addressed here is the long term stability of biomarkers after years of storage. Addressing this variable was beyond the scope of the present study. Use of cross-sectional study designs when comparing samples in a longitudinal cohort after three, five or seven years of storage provide an interim workaround until better data on long term stability are available. Thus, comparison can be made of samples of the same age from individuals exhibiting versus not exhibiting a given clinical phenotype is feasible, if imperfect. Certainly, prioritizing analyses to the earliest possible time point is important.
Finally, while commonly known, an important practical aspect in the implementation of such analyses should be reiterated. Logistical constraints on assay manufacturers preclude provision of constant standards from one assay to another purchased a few months or years later. This underlines the importance of establishing substantial aliquots of a single internal lab standard to be used for each assay to allow inter-assay comparison.
Human cohorts generate tens of thousands of biological samples, often at multiple sites. It is impossible to examine samples for all analytes simultaneously. The results above provide the foundation (and confidence) for large scale analyses of panels of inflammatory biomarkers to better understand immunological mechanisms underlying health versus disease. Specifically, the data demonstrate that an extensive panel of pro-inflammatory (CCL2, CXCL10, IL-18, TNFα, IL-6), anti-inflammatory (IL-10, sTNF-RII, IL-1Ra), acute phase proteins (CRP, PTX3) and other biomarkers (sST2, IL-1RAcP) linked to allergy and autoimmunity and other inflammatory diseases in basic discovery research are readily detectable, even in healthy control individuals, and that they remain stable for repeat analysis despite multiple freeze thaw cycles. More frequent and more comprehensive examination of innate immune signatures would greatly enhance the value obtained from large multi-centre human cohort studies.
Study concept and design: KTH, CG, ADB, ABB, RC, LL, DB; Acquisition of data: CG, RC, WPS, LL; Analysis and interpretation of data: CG, PL and KTH; Drafting of the manuscript: CG and KTH; Critical revision of the manuscript for important intellectual content: all authors. All authors read and approved the final manuscript.
The authors declare that they have no competing interests.
Availability of data and materials
All data generated or analyzed are included in this manuscript.
Ethics approval and consent to participate
University of Manitoba Health Research Ethics Board approval was obtained and written informed consent, was received from each participant or their parent prior to enrollment.
Funding was provided by Canada Research Chairs, Canadian Institutes of Health Research and Allergen NCE. The funding bodies played no role in design of the study and collection, analysis, and interpretation of data or writing the manuscript.
- 1.Chawes BL, Stokholm J, Bonnelykke K, Brix S, Bisgaard H. Neonates with reduced neonatal lung function have systemic low-grade inflammation. J Allergy Clin Immunol. 2015;135(1450–1456):e1451.Google Scholar
- 4.Bowatte G, Lodge C, Lowe AJ, Erbas B, Perret J, Abramson MJ, Matheson M, Dharmage SC. The influence of childhood traffic-related air pollution exposure on asthma, allergy and sensitization: a systematic review and a meta-analysis of birth cohort studies. Allergy. 2015;70:245–56.CrossRefPubMedGoogle Scholar
- 7.Cooper PJ, Chico ME, Amorim LD, Sandoval C, Vaca M, Strina A, Campos AC, Rodrigues LC, Barreto ML, Strachan DP. Effects of maternal geohelminth infections on allergy in early childhood. J Allergy Clin Immunol. 2016;137(899–906):e892.Google Scholar
- 8.Gunaratne AW, Makrides M, Collins CT. Maternal prenatal and/or postnatal n-3 long chain polyunsaturated fatty acids (LCPUFA) supplementation for preventing allergies in early childhood. Cochrane Database Syst Rev. 2015;7:CD010085.Google Scholar
- 15.Leng SX, Dandorf S, Li H, Carlson J, Hui J, Mehta SH, Piggott D, Islam S, Manwani B, Kirk GD. Associations of circulating soluble tumor necrosis factor-alpha receptors 1 and 2 with interleukin-6 levels in an aging cohort of injection drug users with or at high risk for HIV infection. AIDS Res Hum Retrovir. 2015;31:1257–64.CrossRefPubMedPubMedCentralGoogle Scholar
- 21.Tomassen P, Vandeplas G, Van Zele T, Cardell LO, Arebro J, Olze H, Forster-Ruhrmann U, Kowalski ML, Olszewska-Ziaber A, Holtappels G, et al. Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers. J Allergy Clin Immunol. 2016;137(1449–1456):e1444.Google Scholar
- 29.Savenije OE, Kerkhof M, Reijmerink NE, Brunekreef B, de Jongste JC, Smit HA, Wijga AH, Postma DS, Koppelman GH. Interleukin-1 receptor-like 1 polymorphisms are associated with serum IL1RL1-a, eosinophils, and asthma in childhood. J Allergy Clin Immunol. 2011;127(750–756):e751–5.Google Scholar
- 31.Savenije OE, Mahachie John JM, Granell R, Kerkhof M, Dijk FN, de Jongste JC, Smit HA, Brunekreef B, Postma DS, Van Steen K, et al. Association of IL33-IL-1 receptor-like 1 (IL1RL1) pathway polymorphisms with wheezing phenotypes and asthma in childhood. J Allergy Clin Immunol. 2011;134:170–7.CrossRefGoogle Scholar
- 33.Moraes TJ, Lefebvre DL, Chooniedass R, Becker AB, Brook JR, Denburg J, HayGlass KT, Hegele RG, Kollmann TR, Macri J, et al. The Canadian healthy infant longitudinal development birth cohort study: biological samples and biobanking. Paediatr Perinat Epidemiol. 2015;29:84–92.CrossRefPubMedGoogle Scholar
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.